Antigen-directed single domain antibody-based TNFR1 agonists elicit preferential killing of HER2-overexpressing cancer cells

iScience 2026 Open access

Read full text
Authors: Laura Unmuth, Britta Lipinski, Alicia Hoerr, Julia Harwardt, Enrico Guarnera, Michal Szczepek, Stefan Becker, Andreas Menrad, Patrick Scheerer, Andreas Evers, Simon Krah, Desislava Elter
+2 more Lukas Pekar, Stefan Zielonka
DOI: 10.1016/j.isci.2026.115327
Cited by: 2
References: 82

Abstract

-targeted manner. By modulating the valency of the TNFR1-directed sdAb, killing capacities as well as caspase activities of HER2-targeted ICMs were significantly augmented, eventually resulting in enhanced cell death induction when compared with TNF. Moreover, HER2-targeted TNFR1 ICMs also displayed a beneficial, i.e., substantially reduced profile in inducing unconditional pro-inflammatory cytokine release from peripheral blood mononuclear cells (PBMCs).

Fields of Study & Subjects

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
4
Pages
115327–115327
Publication date
11 March 2026
Language
EN